CARsgen Therapeutics Holdings Limited (HK:2171), a Chinese developer of innovative CAR T-cell therapies, announced on Saturday that satricabtagene autoleucel (satri-cel, product code: CT041), an autologous CAR T-cell therapy product targeting Claudin18.2, has been included in the latest Commercial Health Insurance Innovative Drug List (CHIIDL) issued by the National Healthcare Security Administration (NHSA) and the Ministry of Human Resources and Social Security (MOHRSS), for the treatment of patients with Claudin18.2-positive, HER2-negative advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) who have failed at least two prior lines of therapy.
The new list will officially take effect in January 2027.
The CHIIDL primarily covers innovative drugs that go beyond the 'basic coverage' mandate of the national basic medical insurance scheme and therefore cannot yet be included in the basic reimbursement list, but which are highly innovative, of significant clinical value, deliver substantial patient benefit, and are well suited to insurance coverage. It provides a payment basis for China's multi-tiered healthcare security system, including commercial health insurance and mutual medical aid.
According to CARSgen, satri-cel is the first CAR T-cell therapy product for solid tumors to be included in the CHIIDL since the list was established, marking an extension of the multi-tiered healthcare security system's support for CAR T-cell therapy from hematologic malignancies into solid tumors, which affect a considerably larger patient population.
CARsgen said that it is actively expanding satri-cel application in early-line treatment and perioperative treatment of cancer, including an ongoing Phase I clinical trial for pancreatic cancer adjuvant therapy in China, an IIT for consolidation treatment following adjuvant therapy in patients with resected G/GEJA and an IIT for sequential therapy following first-line treatment for G/GEJA.
Guardant Health expands liquid biopsy test with AI-powered epigenomic applications
Nuvation Bio to present at Jefferies Global Healthcare Conference in London
Illumina expands MRD research portfolio with ultrasensitive sequencing technology
Photocure maintains 2028 Medicare coverage target for AssureMDx following CMS update
Akeso publishes ivonescimab Phase II study results in Nature Medicine
INOVIO prices public offering of approximately USD75m
First patient dosed in Phase 1 trial of Transgene and BioInvent's BT-001 for rectal cancer
Elicera Therapeutics secures Chinese patent allowance for ELC-401
CHOSA Oncology signs US laboratory agreement for Platin-DRP commercialisation
BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma
Pentixapharm advances preparationsfor Phase 3 PANDA study
CStone and Kimia Therapeutics collaborate to advance oncology drug candidate
Vivesto secures US orphan drug designation for Cantrixil in acute myeloid leukemia